• 1
    Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33:130137.
  • 2
    Sibai BM: Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 2008; 52:805806.
  • 3
    Roberts JM, Cooper DW: Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357:5356.
  • 4
    Goldenberg RL, Culhane JF, Iams JD, Romero R: Epidemiology and causes of preterm birth. Lancet 2008; 371:7584.
  • 5
    FDA grants fast track review to Glenveigh Digoxin Immune Fab. Pharmaceutical Business Review. November 13, 2012. Accessed December 14, 2012.
  • 6
    Duley L, Henderson-Smart DJ, Meher S, King JF: Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;2: CD004659.
  • 7
    Urban G, Vergani P, Tironi R, Ceruti P, Vertemati E, Sala F, Pogliani E, Triche EW, Lockwood CJ, Paidas MJ: Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy. Int J Fertil Womens Med 2007; 52:5967.
  • 8
    Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn SR, Magee LA, Rodger M: Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7:5864.
  • 9
    Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene Montella K, Greer I: Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 2008; 112:320324.
  • 10
    Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Siba BM: Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2004; 190:15901595. Discussion 1595–1597.
  • 11
    Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grové D: Expectant management of early onset, severe pre-eclampsia: perinatal outcome. BJOG 2000; 107:12581264.
  • 12
    Witlin AG, Saade GR, Mattar F, Sibai BM: Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2000; 182:607611.
  • 13
    Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM: Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol 1999; 180:221225.
  • 14
    Visser W, Wallenburg HC: Maternal and perinatal outcome of temporizing management in 254 consecutive patients with severe pre-eclampsia remote from term. Eur J Obstet Gynecol Reprod Biol 1995; 63:147154.
  • 15
    Sibai BM, Taslimi M, Abdella TN, Brooks TF, Spinnato JA, Anderson GD: Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester. Am J Obstet Gynecol 1985; 152:3237.
  • 16
    Sibai BM, Mercer BM, Schiff E, Friedman SA: Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171:818822.
  • 17
    Bombrys AE, Barton JR, Nowacki EA, Habli M, Pinder L, How H, Sibai BM: Expectant management of severe preeclampsia at less than 27 weeks' gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol 2008;199:247 e16.
  • 18
    Sibai BM: Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 2011; 205:191198.
  • 19
    Weiner CP, Kwaan HC, Xu C, Paul M, Burmeister L, Hauck W: Antithrombin III activity in women with hypertension during pregnancy. Obstet Gynecol 1985; 65:301306.
  • 20
    Maclean PS, Tait RC: Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007; 67:14291440.
  • 21
    Buller HR, Weenink AH, Treffers PE, Kahlé LH, Otten HA, ten Cate JW: Severe antithrombin III deficiency in a patient with pre-eclampsia. observations on the effect of human AT III concentrate transfusion. Scand J Haematol 1980; 25:8186.
  • 22
    Terao T, Kobayashi T, Imai N, Oda H, Karasawa T: Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT III concentrate. Asia-Oceania J Obstet Gynaecol 1989; 15:2532.
  • 23
    Nakabayashi M, Asami M, Nakatani A: Efficacy of antithrombin replacement therapy in severe early-onset preeclampsia. Semin Thromb Hemost 1999; 25:463466.
  • 24
    Kobayashi T, Terao T, Ikenoue T, Sameshima H, Nakabayashi M, Kajiwara Y, Maki M: Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost 2003; 29:645652.
  • 25
    Kobayashi T, Terao T, Ikenoue T, Kajiwara Y, Maki M: Antithrombin therapy for preeclampsia. Biomed Prog 2003; 16:7277.
  • 26
    Kobayashi T: Antithrombin abnormalities and perinatal management. Curr Drug Targets 2005; 6:559566.
  • 27
    Maki M, Kobayashi T, Terao T, Ikenoue T, Satoh K, Nakabayashi M, Sagara Y, Kajiwara Y, Urata M: Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. BI51.017 Study Group. Thromb Haemost 2000; 84:583590.
  • 28
    Paternoster DM, Fantinato S, Manganelli F, Milani M, Nicolini U, Girolami A: Efficacy of AT in pre-eclampsia: a case-control prospective trial. Thromb Haemost 2004; 91:283289.